Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Confusion Over Anti-Clotting Therapy Hinders Drug-Eluting Stent Rebound

This article was originally published in The Gray Sheet

Executive Summary

Blanket recommendations for one year of dual antiplatelet therapy for patients who receive drug-eluting stents may be the biggest cloud over the market for the devices, cardiologists suggest

You may also be interested in...

Starts & Stops: Abbott, Boston Scientific Head List Of Early 2018 Trial Announcements

Starts & Stops is a regular feature in Medtech Insight highlighting noteworthy clinical trial announcements, initiations, completions, and suspensions tracked by Meddevicetracker. This edition covers the start of 2018, which includes important trial announcements from Abbott, Boston Scientific, Medtronic, Edwards and many more. The Stops & Starts feature will be switching to a weekly schedule as of March 5 to offer more timely updates on medical device trials.

Longer Anti-Platelet Therapy Reduces Thrombosis Risks With Drug-Eluting Stents

In patients implanted with drug-eluting stents, dual antiplatelet drug therapy beyond one year significantly reduces the risks of stent thrombosis and major adverse cardiovascular and cerebrovascular events compared to aspirin alone, but also increase the risk of bleeding, the Dual Antiplatelet Therapy Trial show.

FDA Contributes Funds To Industry Post-Stenting Antiplatelet Trial

FDA is contributing $1.5 million to a large, collaborative clinical study designed to find out the optimum length of time to give anti-clotting drugs to patients with coronary drug-eluting stents

Related Content




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts